NICM
ACAD icon

Neo Ivy Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Neo Ivy Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-32,036
Closed -$713K – 348
2026
Q1 		$713K Buy
32,036
+26,028
+433% +$622K 0.19% 179
2025
Q4 		$160K Sell
6,008
-56,560
-90% -$1.35M 0.03% 284
2025
Q3 		$1.34M Buy
+62,568
New +$1.48M 0.33% 115
2025
Q1 		– Sell
-57,504
Closed -$1.05M – 272
2024
Q4 		$1.05M Buy
57,504
+54,022
+1,551% +$872K 0.21% 154
2024
Q3 		$54K Sell
3,482
-199,566
-98% -$3.33M 0.02% 245
2024
Q2 		$3.3M Buy
+203,048
New +$3.28M 0.65% 68
2023
Q4 		$0 Buy
+3
New +$72 ﹤0.01% 276
2023
Q3 		– Sell
-36,483
Closed -$874K – 310
2023
Q2 		$874K Buy
+36,483
New +$811K 0.46% 70
2022
Q3 		– Sell
-324
Closed -$4K – 370
2022
Q2 		$4K Sell
324
-1,260
-80% -$23.5K 0.01% 357
2022
Q1 		$38K Sell
1,584
-1,682
-52% -$40.7K 0.03% 392
2021
Q4 		$76K Buy
+3,266
New +$65.7K 0.11% 246
2021
Q3 		– Sell
-252
Closed -$6K – 441
2021
Q2 		$6K Sell
252
-6,006
-96% -$136K 0.01% 404
2021
Q1 		$161K Buy
6,258
+1,979
+46% +$87.1K 0.18% 189
2020
Q4 		$229K Buy
4,279
+1,086
+34% +$53.9K 0.26% 141
2020
Q3 		$131K Buy
+3,193
New +$138K 0.13% 248
2020
Q2 		– Sell
-6,661
Closed -$281K – 442
2020
Q1 		$281K Buy
+6,661
New +$274K 0.46% 66
2019
Q3 		– Sell
-16,832
Closed -$450K – 274
2019
Q2 		$450K Buy
16,832
+14,391
+590% +$368K 0.25% 168
2019
Q1 		$65K Buy
+2,441
New +$57K 0.04% 244

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Neo Ivy Capital Management's ACAD Position: Q2 2026 in Review

Neo Ivy Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q2 2026, closing a stake of 32,036 shares — an estimated $713K sold.

Neo Ivy Capital Management first reported a position in ACAD in Q1 2019 and held it in 18 quarters. The position peaked at $3.3M in Q2 2024. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Neo Ivy Capital Management reported no remaining Acadia Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Neo Ivy Capital Management sold 32,036 Acadia Pharmaceuticals shares in Q2 2026, an estimated $713K.
  • Neo Ivy Capital Management first reported a position in Acadia Pharmaceuticals in Q1 2019 and held it in 18 quarters.
  • Neo Ivy Capital Management's Acadia Pharmaceuticals position peaked at $3.3M in Q2 2024.
  • 353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Neo Ivy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.